A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-06-29
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-09 (study day 53); relationship: not assessed
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-16 (study day 363); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 441); relationship: N
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-14 (study day 453); relationship: N
Data queries
No data queries.